Despite the recent tech sell-down, Frencken Group remains attractive with strong potential in its medical and semiconductor segments, says RHB Group Research analyst Jarick Seet. 

Seet is maintaining “buy” on the technology solutions company, with a target price of $1.52.

“On March 8, we hosted Frencken Group for a non-deal roadshow (NDR) and came away feeling more confident of our bullish call despite the recent tech sell-down. We estimate this is an opportunity to purchase shares at a more attractive level and remain positive on its growth this year,” writes Seet in a March 9 note. 

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook